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Abstract
Fibroblasts derived from the progeroid Werner syndrome show reduced replicative lifespan and a “stressed”
morphology, both alleviated using the MAP kinase inhibitor SB203580. However, interpretation of these data is
problematical because although SB203580 has the stress-activated kinases p38 and JNK1/2 as its preferred targets,
it does show relatively low overall kinase selectivity. Several lines of data support a role for both p38 and JNK1/2
activation in the control of cellular proliferation and also the pathology of diseases of ageing, including type II
diabetes, diseases to which Werner Syndrome individuals are prone, thus making the use of JNK inhibitors
attractive as possible therapeutics. We have thus tested the effects of the widely used JNK inhibitor SP600125 on
the proliferation and morphology of WS cells. In addition we synthesised and tested two recently described
aminopyridine based inhibitors. SP600125 treatment resulted in the cessation of proliferation of WS cells and
resulted in a senescent-like cellular phenotype that does not appear to be related to the inhibition of JNK1/2. In
contrast, use of the more selective aminopyridine CMPD 6o at concentrations that fully inhibit JNK1/2 had a
positive effect on cellular proliferation of immortalised WS cells, but no effect on the replicative lifespan of primary
WS fibroblasts. In addition, CMPD 6o corrected the stressed WS cellular morphology. The aminopyridine CMPD 6r,
however, had little effect on WS cells. CMDP 6o was also found to be a weak inhibitor of MK2, which may partially
explain its effects on WS cells, since MK2 is known to be involved in regulating cellular morphology via HSP27
phosphorylation, and is thought to play a role in cell cycle arrest. These data suggest that total JNK1/2 activity
does not play a substantial role in the proliferation control in WS cells.
Findings
Werner syndrome (WS) is a genetic disorder where indivi-
duals show premature onset of many clinical features of
old age and is used as a model to investigate normal aging
processes [1]. The molecular mechanism of WS is related
to accelerated cell aging. Normal human cells divide a lim-
ited number of times before entering replicative senes-
cence [2]. This is postulated to contribute to normal
human aging [1] and fibroblasts from WS patients have a
much-reduced replicative life span [3]. This premature
senescence of WS cells is thought to be a stress response,
and the stress-induced p38 MAPK pathway is activated in
young WS cells [3]. Treatment with the p38 inhibitor
SB203580 increases the growth rate and the cellular life
span of primary WS cells to within the range seen for nor-
mal fibroblasts, and rescues their senescent-like morphol-
ogy [3,4]. Essentially, SB203580 reverts the phenotypic
characteristics of WS fibroblasts, implicating a role for
both p38 and stress signalling in WS.
Although we have shown that p38 is up-regulated in
WS cells, consistent with a role for p38 activation in the
accelerated senescence of WS cells [3], SB203580 is
known to inhibit other kinases involved in cellular prolif-
eration control, in particular the stress activated JNK1/2
and the CK1 isoforms [5,6], although the involvement of
the latter in WS accelerated cell senescence has been
ruled out [7]. JNK1/2 are known to activate p53 as a
result of increased pro-oxidant state or UV exposure
[8,9], and also phosphorylate and stabilise the cyclin
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WAF1 [10] that is up-
regulated at (and can induce) cellular senescence [11]. In
addition, expression of a constitutively active MKK7 (a
JNK1/2 kinase) leads to inhibition of cell proliferation
[12]. These data suggest a role for JNK1/2 in cell cycle
arrest in some situations and are consistent with reports
that JNK1/2 are not activated in normal fibroblasts,
either from young individuals or at low population dou-
blings, but are up-regulated in fibroblasts from aged indi-
viduals [13,14] and in senescent WS AG03141 and
MRC5 fibroblasts (Figure 1a). Levels of activated JNK1/2
a n dc - J u na r ea l s oe l e v a t e di na g e ds k i nin vivo [13,15].
Thus the available published data support a role for
JNK1/2 in cellular ageing. As JNK1/2 are activated in low
PD AG03141 fibroblasts but not in low PD MRC5 cells
(Figure 1a), it is plausible that the effect on WS cells of
SB203580 is, at least in part, via inhibition of JNK1/2.
Thus we have undertaken a series of experiments using
small molecule inhibitors to assess the possible role of
JNK1/2 in the proliferation of WS cells (see Additional file
1 for materials and methods). Due to the short supply of
primary WS cells, AG03141 cells that have been immorta-
lised using human telomerase (hTERT) have been used to
test the effectiveness of inhibitors on cell proliferation
prior to using primary cells. AG03141.tert cells preserve
the essential features of slow growth rates and aged mor-
phology of primary AG03141 cells [16] and have activated
JNK1/2 (Figure 1a).
The most widely used JNK inhibitor is the commercially
available anthrapyrazolone SP600125 [17]. Prior to looking
at the effects on cell proliferation we titrated the effective-
ness of SP600125 to inhibit the anisomycin-induced phos-
phorylation of c-Jun (Figure 1b). As can be seen, although
it does inhibit JNK1/2, SP600125 has relatively low
potency, only fully inhibiting JNK1/2 activity above 10
μM, in agreement with previous studies that use SP600125
at 25 μM to fully inhibit JNK1/2 [17]. SP600125 treatment
of WS AG03141.tert cells has an increasingly inhibitory
effect on proliferation with concentrations of 10 μMa n d
above resulting in complete growth cessation (Figure 1c).
At 1.0 and 2.5 μM proliferation of the cells is slowed initi-
ally with the cells eventually ceasing proliferation after
30 days. The cellular morphology is altered at 10 μM
SP600125 in that the cells resemble the senescent state,
being enlarged and granular (not shown). These data sug-
gest that SP600125 is inducing a cellular senescence-like
state in the cells. The cause of this proliferation cessation
is unknown, but may not be related to JNK1/2 inhibition,
as total JNK activity is not fully inhibited at SP600125 con-
centrations sufficient to cause the proliferation cessation.
However, it has become increasingly clear that SP600125
has low specificity for JNK1/2 [18]. Of particular concern
is that SP600125 inhibits the kinases cdk2 and CK1δ better
than JNK1/2, because cdk2 activity is important for cell
cycle progression [19] and CK1δ activity is necessary for
cell cycle progression and cellular proliferation as shown
by CK1δ inhibition causing growth arrest [20].
We therefore need JNK inhibitors with improved effi-
cacy and specificity profiles to dissect the possible role
for JNK1/2 in WS cell growth. There have been extensive
efforts by Pharma to develop novel JNK1/2 inhibitors
including, recently, a set of diaminopyridine inhibitors
that fits this profile [21]. We therefore synthesised two
aminopyridine inhibitors, compound (CMPD) 6o (1) and
6r (2) (Figure 1d) respectively, according to the reported
method [21]. These compounds inhibit the activity but
not activation of JNK1/2 as shown by JNK1/2 phosphory-
lation and c-Jun phosphorylation, with IC50 values of
approximately 1.5 μM in agreement with [21], with maxi-
mal inhibition at 10 μM for each inhibitor (Figure 1e, f).
Treatment of AG03141.tert cells with inhibitor 1 at 10
or 25 μM increased their growth rates, although not to the
extent seen with SB203580 (Figure 1g). Thus, we tested
the effects of 1 on the lifespan of primary WS cells. Con-
trol AG03141F cells have a total lifespan of 16.5 PD
(including the 12 PD that the cells achieved prior to
receipt from the Coriell Cell Repository); this is increased
to 26.3 PD by the use of SB203580 (Figure 1h). Inhibitor 1
at 10 μM had no effect on the growth rate or lifespan of
AG03141F cells compared to the DMSO control (Figure
1h), whereas at 25 μM growth was arrested (not shown).
Cellular morphology in control AG03141F cultures was
one of enlarged cells with F-actin stress fibres; treatment
with 1 resulted in a reversion to the small cell morphology
and sparse F-actin stress fibres that is characteristic of
wild-type fibroblasts (Figure 1j: see [4] for morphology of
normal fibroblasts).
JNK1/2 have not been reported to affect F-actin stress
fibre production. Unexpectedly (see [21]), it was found
that in addition to inhibiting JNK1/2, inhibitor 1 inhibits
the p38-signalling pathway as assessed by the prevention
of anisomycin-induced HSP27 phosphorylation (Figure
1i). On further analysis, inhibitor 1 appears to be a weak
inhibitor of MK2 (the major HSP27 kinase), because it
does not prevent the activation of MK2 by p38 (as shown
by the continued presence of the band shift indicative of
MK2 phosphorylation at high 1 concentrations; see Fig-
ure 1k lane 4), but instead prevents the phosphorylation
of HSP27 (Figure 1k).
In contrast inhibitor 2 had little effect on the prolif-
eration of AG03141.tert cells up to 10 μM, although it
is growth inhibitory at 25 μM (Figure 1g), a point that
coincides with activation of the p38 pathway (Figure 1i).
Inhibitor 2 slightly reduced the replicative lifespan of
AG03141F cells (Figure 1h), but had very little effect on
the cellular morphology phenotype (Figure 1j).
Overall the data suggest that total JNK1/2 activity is
not involved in the slow growth phenotype of WS cells,
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Page 2 of 5Figure 1 Effects of JNK inhibitors on the proliferation and morphology of WS cells. (a) immunoblot showing activation of JNK1/2 in
AG03141 WS primary cells, MRC5 cells, and AG03141.tert cells ("y” and “s” are low PD and senescent cells respectively; p-JNK1/2 = activated
JNK1/2). (b) Immunoblot showing inhibition of anisomycin-induced JNK1/2 activity by SP600125 as measured by c-Jun phosphorylation (p-c-Jun
= activated c-Jun). (c) Effects of SP600125 on the proliferation of AG03141.tert cells (closed triangles represent SP600125 at 10, 25 or 50 μM). (d)
Structure of the aminopyridine JNK inhibitors. (e) Titration inhibition of JNK1/2 profile by 1 and 2 as measured by c-Jun phosphorylation ELISA.
(f) Immunoblot showing inhibition of JNK1/2 in AG03141.tert cells by 1 and 2 (p-c-Jun = activated c-Jun; arrow shows p-c-Jun). (g) Effects of 1
and 2 on the growth rate of AG03141.tert cells measured as percentage of DMSO control (SB = SB203580 treated cells). (h) Effects of 1 and 2
on the replicative lifespan of primary AG03141F cells. (i) Titration inhibition of the p38 pathway profile by 1 and 2 as measured by HSP27
phosphorylation. (j) F-actin stress fibre phenotype of primary AG03141F cells (left) and the effects of 1 at 25 μM (middle) and 2 at 10 μM (right).
(j) Immunoblot showing inhibition of MK2 by 1( p-p38 and p-HSP27 are activated p38 and HSP27; p-MK2 upper band is activated MK2).
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the observation that complete inhibition of JNK1/2
using 1 and 2 does not result in cell cycle arrest, sug-
gests that the proliferation arrest resulting from
SP600125 use is not through inhibition of JNK1/2, a
possibility supported by recent data showing that
SP600125 can induce a G2/M cell cycle arrest via
p21
WAF1 expression and cdk2 inhibition, although the
mechanism is not fully understood [22].
However, as both 1 and 2 completely inhibit both
JNK1 and JNK2 at 10 μM, these data do not rule out
the possibility that individual JNK isoforms may be
separately involved. On this note data from mouse JNK
knockouts suggest that JNK1 promotes whereas JNK2
inhibits proliferation in mouse fibroblasts [23]. In addi-
tion, as more data is obtained it is increasingly clear
that the biological role of JNKs in human disease pro-
cesses may well be isoform specific [24]. Thus as
SB203580 preferentially inhibits JNK2 isoforms at the
concentration where it is most effective in WS cells
[3,5,18], it may be that the effectiveness of SB203580 on
the prevention of accelerated ageing in WS fibroblasts
results from the inhibition of both p38 and JNK2 iso-
forms. Thus, inhibitors that can target each specific JNK
isoform separately are necessary to dissect out these
individual roles [24].
In conclusion we have synthesised two potent and
selective JNK inhibitors and tested their effects on the
proliferation of WS cells. While our data exclude a role
for total JNK activity on WS cell proliferation or mor-
phology, they do suggest a possible role for MK2. It can-
not be excluded that JNK is involved in WS cell growth,
but in an isoform-specific manner, a possibility that can
only be addressed once suitable isoform-specific inhibi-
tors become available. Finally, these data illustrate the
greater utility of these diaminopyridine inhibitors for the
study of the role of JNKs in biological systems, rather
than the anthrapyrazolone SP600125.
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